Daily BriefsJapan

Daily Brief Japan: NTT Data Corp, Seven Bank Ltd, Nippon Steel Corporation, Nippon Building Fund, Allegro MicroSystems , Olympus Corp and more

In today’s briefing:

  • [Japan Event] Potentially Interesting Dynamics of Post-Tender NTT Data (9613) Trading. $8bn+ One Way
  • [Japan Event] Seven Bank (8410) To Buy Back Up to 17.0% of Shares Out Tomorrow
  • Nippon Steel (5401 JP) – No Rival, No Discount, Limited Control
  • Nippon Building Fund Placement – Small Deal but Lacks Accretion
  • Allegro MicroSystems: China-for-China Strategy to Harness Growth In One Of The World’s Largest Semiconductor Markets!
  • Olympus Corp (7733 JP): Forex Holds FY25 Together; FY26 Guidance Does Not Offer Much Respite


[Japan Event] Potentially Interesting Dynamics of Post-Tender NTT Data (9613) Trading. $8bn+ One Way

By Travis Lundy

  • The NTT Data Corp (9613 JP) Tender Offer closed today. Results will come out tomorrow. I expect it will have been successful. 
  • That will mean some US$8bn+ of passive tracking flows to sell and $8bn+ to buy related to this event alone in the next 3 months. 
  • And there are some very interesting dynamics to consider in the meantime. 

[Japan Event] Seven Bank (8410) To Buy Back Up to 17.0% of Shares Out Tomorrow

By Travis Lundy

  • Today after the close, Seven Bank Ltd (8410 JP) announced a MASSIVE ToSTNeT-3 transaction to buy back up to 200,000,000 shares (17.0% of shares out) for ¥52.4bn. Tomorrow AM. 
  • There is a complex iterative calculation on the part of Seven Eleven Japan to figure out how many shares they should put into the buyback.
  • I see a minimum buyback of 10.8%. 17% would be great. But there is a potential issue on the back end of which investors should be aware.

Nippon Steel (5401 JP) – No Rival, No Discount, Limited Control

By Rahul Jain

  • Nippon paid full price despite governance restrictions; with no credible rival, rejecting the golden share risked collapsing the deal.
  • Historical golden share precedents imply 10–20% valuation discounts, yet Nippon accepted late-stage constraints without renegotiation.
  • Funding mix includes bridge loans, hybrids, and asset sales, but proposed equity issuance near 40% below book risks EPS dilution and undermines capital discipline messaging.

Nippon Building Fund Placement – Small Deal but Lacks Accretion

By Sumeet Singh

  • Nippon Building Fund (8951 JP) is looking to raise around US$122m in its Primary Offering, to fund the acquisition of Frontier Musashikosugi N Building and S Building.
  • Unusually for Japan, the acquisition was announced at the end of last month, while the raising has only been announced today.
  • In this note, we talk about the deal dynamics and run the deal through our ECM framework.

Allegro MicroSystems: China-for-China Strategy to Harness Growth In One Of The World’s Largest Semiconductor Markets!

By Baptista Research

  • Allegro MicroSystems has reported its financial results for the fourth quarter and the full fiscal year 2025.
  • The company is focused on strengthening its market position through innovation and operational efficiencies.
  • President and CEO Mike Doogue, who ascended from being the company’s first Chief Technology Officer, emphasized a strategic focus on expanding product capabilities and extending Allegro’s footprint in lucrative markets such as automotive, industrial, and emerging sectors like medical and robotics.

Olympus Corp (7733 JP): Forex Holds FY25 Together; FY26 Guidance Does Not Offer Much Respite

By Tina Banerjee

  • Olympus Corp (7733 JP) witnessed revenue grow 8% YoY to ¥997B (3% on Fx neutral basis) in FY25, driven by both the Endoscopic Solutions and Therapeutic Solutions divisions.
  • North America sales growth continues to be favorable in warding off the decline faced in China. GI Endoscopy (55% of ESD revenue) witnessed its revenue grow 8% to ¥350B.
  • Olympus guided FY26 revenue to be flat YoY at ¥999B. R&D expenses are expected to rise, scarring the margins. Adjusted operating profit margin is expected to be 17.5% (FY25: 18.9%).

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars